The truism about biopharma being a global industry has never been truer than when it comes to the top 20 IPOs for the first half of this year.
The U.S. had exactly half of the therapeutic, diagnostics, and tools/tech IPOs that were completed or began trading their first shares on public markets during January-June 2015. The rest of the world accounted for the other half, with Europe being home to seven of the 10 ex-U.S. top IPOs, followed by China, Canada, and Bermuda with one each.